200 filings
Page 2 of 10
SC 13G/A
5l14apbuubp9zsub6l0j
2 Jan 24
ASLAN Pharmaceuticals / TANG CAPITAL PARTNERS ownership change
4:00pm
6-K
yxp mw7lt2kketfuy9i
22 Dec 23
Current report (foreign)
4:24pm
6-K
l0pih
8 Dec 23
Current report (foreign)
4:42pm
6-K
hzm2grr0
27 Oct 23
Aslan Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
8:14am
6-K
u37n6
24 Oct 23
Aslan Pharmaceuticals to Co-host Kol Panel Discussion Today on Changes In the Clinical Trial and Treatment Landscape for Atopic Dermatitis
8:32am
6-K
rlfumj ocwjo4
16 Oct 23
Current report (foreign)
6:08am
6-K/A
hm5bb2noi z7o80ng7ns
18 Aug 23
Current report (foreign) (amended)
7:33am
6-K
fkvd2u
11 Aug 23
Aslan Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:10am
6-K
evz7p4z
20 Jul 23
Current report (foreign)
7:55am
SC 13G/A
hcuc73p5djbmfc42c15f
13 Jul 23
ASLAN Pharmaceuticals / TANG CAPITAL PARTNERS ownership change
4:57pm
6-K
jfi fzby9ndv8n4zm49a
6 Jul 23
Current report (foreign)
8:11am
424B5
kidopwshe0bnnj
6 Jul 23
Prospectus supplement for primary offering
8:09am
6-K
7u32om2s pvf1i
6 Jul 23
Current report (foreign)
7:59am
6-K
zur91liu yt
3 Jul 23
Current report (foreign)
4:15pm
6-K
t92p5 0cghm
22 Jun 23
Aslan Pharmaceuticals Enters into a Strategic Licensing Deal with Zenyaku Kogyo for the Development and Commercialization of Eblasakimab In Japan
8:32am
6-K
9wye9wpl23qducuv2q12
28 Apr 23
Aslan Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
7:29am
F-6EF
iq0649di8rqbvib
26 Apr 23
Automatic registration for ADRs (foreign)
5:26pm
D
ixts2
26 Apr 23
$100.00 mm in equity / options / securities to be acquired, sold $20.00 mm, 7 investors
4:27pm
EFFECT
2bdmd8qb
7 Apr 23
Notice of effectiveness
12:15am
EFFECT
zhvczik6m9
7 Apr 23
Notice of effectiveness
12:15am